| Autor: |
Caimi PF; Cleveland Clinic Taussig Cancer Center, Cleveland, OH. caimip@ccf.org., Ai WZ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA., Alderuccio JP; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL., Ardeshna KM; University College London Hospitals NHS Foundation Trust, London, United Kingdom., Hamadani M; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI., Hess B; Medical University of South Carolina, Charleston, SC., Kahl BS; Washington University, St. Louis, MO., Radford J; NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom., Solh M; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA., Stathis A; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna., Wang Y; ADC Therapeutics America, Inc., Murray Hill, NJ., Qin Y; ADC Therapeutics America, Inc., Murray Hill, NJ., Wang L; ADC Therapeutics America, Inc., Murray Hill, NJ., Xu ZC; ADC Therapeutics America, Inc., Murray Hill, NJ., Carlo-Stella C; Department of Biomedical Sciences, Humanitas University, and Department of Oncology and Hematology, Humanitas Research Hospital-IRCCS, Milano. |
| Abstrakt: |
Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor activity in the pivotal phase II LOTIS-2 study in heavily pretreated patients with R/R DLBCL. Here we present updated efficacy and safety analyses from LOTIS-2, performed for all patients and in subsets of patients with a complete response (CR), including patients with CR who were event-free (no progressive disease or death) for ≥1 year and ≥2 years from cycle 1, day 1 of treatment. Lonca was administered every 3 weeks (0.15 mg/kg for 2 cycles; 0.075 mg/kg for subsequent cycles). As of the final data cutoff (September 15, 2022; median follow-up: 7.8 months [range, 0.3-42.6]), 70 of 145 (48.3%) patients achieved an overall response. Thirty-six (24.8%) patients achieved CR, of which 16 (44%) and 11 (31%) were event-free for ≥1 year and ≥2 years, respectively. In the all-treated population, the median overall survival was 9.5 months; the median progression-free survival was 4.9 months. Among patients with CR, median overall survival and progression-free survival were not reached, with 24-month overall and progression-free survival rates of 68.2% (95% CI: 50.0-81.0) and 72.5% (95% CI: 48.2-86.8), respectively. No new safety concerns were detected. With additional follow-up, Lonca continued to demonstrate durable, long-term responses with manageable safety and tolerability in patients with CR (clinicaltrials gov. Identifier: NCT03589469). |
